Teva ‘continues to execute’ on pillars of ‘Pivot to Growth’ strategy

The company said, “Delivering on our growth engines – We continued to showcase strong performance of our key innovative brands, mainly AUSTEDO, AJOVY, and UZEDY collectively, +35% YoY in revenues for 2025. During 2025, the FDA approved an expansion of AJOVY’s indication, to include its use as an anti-CGRP preventive treatment for pediatric episodic migraine, as well as an expansion of UZEDY as treatment for adults living with Bipolar 1 Disorder. Stepping up innovation – We continued to accelerate the development of certain key pipeline assets. Teva (TEVA) submitted a New Drug Application for olanzapine LAI to the FDA in December 2025, and during the year we received FDA fast track designations for both emrusolmin in MSA and our IL-15 for Celiac Disease. Phase 3 programs for duvakitug in ulcerative colitis and Crohn’s disease were initiated, and Teva is working with its partner Sanofi on targeting additional indications. By the end of 2025, we achieved the targeted initial enrollment for adult and pediatric populations for DARI’s Phase 3 trial. In January 2026, we announced a funding agreement to accelerate the development of anti-IL-15 for vitiligo with Royalty Pharma. Sustaining our generics powerhouse – We continued to optimize our generics business and build a strong pipeline of biosimilars; For biosimilars, we launched SELARSDI the biosimilar to Stelara and EPYSQLI the biosimilar to Soliris, and also received EMA approvals for PONLIMSI the biosimilar to Prolia and DEGEVMA the biosimilar to Xgeva. Focusing our business – We are actively transforming and modernizing our business through Teva Transformation programs. On May 7, 2025, we announced that these programs are expected to generate ~$700M of net savings through 2027. In 2025, we achieved $70M in savings and expect to realize two-thirds of the targeted savings by 2026. We continued to optimize our portfolio and global manufacturing footprint. In addition, we continue our deleveraging efforts, reducing our gross debt levels to $16.8B and net debt to $13.3B through cash flow, repayment and refinancing, and optimizing our working capital management. In response to our improved capital structure and stronger underlying performance, our credit ratings were upgraded by one level at three credit ratings agencies in 2025.”